Samsung Biologics has agreed to acquire PolyPeptide Group for CHF 44.31 per share, a 40% premium over the 10 April price, valuing the peptide CDMO at about CHF 1.46 billion. Draupnir Holding has committed its 55.65% stake to the offer, and PolyPeptide's first-half 2026 results show revenue up 41.6%…
Samsung Biologics has agreed to acquire PolyPeptide Group, a CDMO specializing in peptide-based active pharmaceutical ingredients APIs , for CHF 44.31 per share. The offer values the company at about CHF 1.46 billion and represents a 40% premium over the share price recorded on 10 April, when rumours of a possible sale first moved the stock. Samsung Biologics expects the acquisition to be completed by the end of the year, pending shareholder approval.
John Rim, CEO and chairman of the board at Samsung Biologics, said the deal is about adding a modality the company did not own: "This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1"
Samsung Biologics says the acquisition will also expand its geographic reach in the United States, Europe, and India.
PolyPeptide's board has unanimously recommended that shareholders accept the offer, and Draupnir Holding, which owns 55.65% of the company, has committed to tender all its shares. The support of the controlling shareholder makes the outcome of the required shareholder vote a near formality unless a competing offer emerges, but the deal still has conditions to clear before it closes.
For peptide science, the deal is a measure of how far the field has moved from specialty chemistry to industrial scale. Peptide-based APIs are the active ingredients in a class of metabolic medicines built around GLP-1 , a peptide hormone, and the manufacturing capacity to make those molecules at commercial scale has become a strategic asset. A South Korean CDMO whose business has been built on biologic medicines is paying a premium to enter that market.
The offer price of CHF 44.31 per share is the central number in the transaction, and how it is measured matters. The reference point is CHF 31.65, the price at which PolyPeptide shares traded on 10 April, the day the sale rumours began. The 40% premium is calculated against that price, and against nothing else disclosed.
A premium measured from a rumour-driven price is a conservative measure. The share price on 10 April already embedded the market's expectation that a sale might occur, and the price agreed months later reflects what a strategic buyer was ultimately willing to pay. Whether the pre-rumour trading price stood above or below CHF 31.65 is not disclosed, so the true premium relative to where the stock traded before any takeover speculation cannot be derived from the figures in hand.
The CHF 1.46 billion equity value follows directly from the per-share price, and it is the number long-term investors will weigh against PolyPeptide's financial trajectory. The company has just reported sharply rising revenue and a return to profit, which is the context the board will use to argue that the price captures value for shareholders who sell now while leaving the risks of execution to the buyer.
What the buyer gets for that price is a CDMO whose business is concentrated in peptide APIs, with 37 Phase III projects, revenue concentrated in metabolic therapeutics, and a customer base dominated by large pharmaceutical companies. The premium reflects the scarcity of assets of this kind: dedicated peptide manufacturing know-how cannot be bought off the shelf, and building it in-house would take years of process development and regulatory qualification.
The public record of this transaction begins on 10 April, when PolyPeptide shares stood at CHF 31.65 and sale rumours began to circulate. For months the company did not confirm the identity of any buyer or the terms of any offer. The new disclosures finally name Samsung Biologics as the acquirer, set the price at CHF 44.31 per share, and confirm that Draupnir Holding, with a 55.65% stake, has committed to tender all of its shares.
The sequence matters for understanding the premium. Shares bought at the first appearance of rumours carried the risk that no deal would emerge, and the offer price compensates that risk with a 40% gain. For Draupnir, the commitment to tender removes the possibility that the transaction fails at the shareholder vote. For minority holders, the board's unanimous recommendation and the majority owner's commitment together create a strong presumption that the offer will succeed if the remaining conditions are met.
The conditions themselves are only partially disclosed. The transaction requires shareholder approval, which the board has recommended, and Samsung Biologics expects completion by the end of the year, though the year is not stated. Whether regulatory or competition clearances are needed in any jurisdiction has not been announced. In a deal of this size, spanning a Korean buyer and a European target with operations in the US and India, merger control review in multiple jurisdictions is a normal expectation, but the absence of any stated timeline for such reviews leaves the schedule open.
PolyPeptide reported revenue of €236.6 million for the first half of 2026, an increase of 41.6% over 1H 2025. The arithmetic of that growth rate implies prior-year first-half revenue of roughly €167 million, making the current-year figure not a recovery but an acceleration. In 1H 2025 the company recorded a loss of €26 million; in 1H 2026 it recorded an approximate profit of €9 million.
The swing from a loss of €26 million to a profit of roughly €9 million on revenue that grew by 41.6% indicates that fixed costs are being spread over a much larger revenue base, the classic signature of improved capacity utilization in a contract manufacturing business. The disclosed figures do not break down volume, pricing, or product mix, so part of the growth could reflect price increases or higher-margin project work, but the scale of the swing points primarily to a busier plant.
The revenue mix is where the strategic story becomes visible. Metabolic therapeutics accounted for about 68% of PolyPeptide's total revenues, making the GLP-1 drug class the dominant commercial engine of the company. Large pharma companies represented about 72% of an unspecified base, a concentration that carries both benefits and risks: a handful of large customers provide a dependable order book, but the loss of any one of them would move the revenue line noticeably. The disclosure describes both percentages as approximate, and the base for the 72% figure is not defined.
Releasing the results alongside the transaction terms was deliberate. Shareholders are being asked to vote on the offer with the company's most recent performance in front of them, and the numbers support the board's recommendation. The 41.6% revenue growth is the strongest public evidence that the metabolic wave in peptide drugs is translating into contract manufacturing revenue, which is precisely the trend the offer price capitalizes on.
Peptide APIs occupy a middle ground between small-molecule drugs and biologic proteins. They are chains of amino acids, typically in the range of five to fifty residues, that exert their effects by binding to specific receptors in the body. Their selectivity for those receptors is a function of their length and three-dimensional structure, but the same properties rule out the standardized chemical manufacturing used for most small molecules.
GLP-1, the modality singled out in the acquisition announcement, is an incretin hormone of about thirty amino acids. After food intake, it is released from intestinal L cells and acts through the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. Peptide drugs that mimic this signaling pathway are now central to the treatment of type 2 diabetes and obesity, and their active ingredients are long-chain peptides that must be manufactured under conditions far stricter than those for typical chemical drugs.
Manufacturing a peptide API is an exercise in impurity control. Solid-phase peptide synthesis builds the chain stepwise on a resin, adding one amino acid at a time. Each coupling can fail or proceed incompletely, generating deletion sequences; side chains can react in unintended ways; and the desired product itself can racemize or oxidize. The crude mixture that emerges after cleavage is far from pure, and bringing it to regulatory quality requires preparative chromatography, followed by extensive analytical characterization to demonstrate sequence identity, purity, and the absence of process-related impurities. The longer the peptide, the worse the impurity burden and the harder the purification.
Scale-up adds another layer. A synthesis that works at gram scale in the laboratory does not necessarily behave the same at the hundred-kilogram scale required for a commercial metabolic drug. Impurity profiles shift with scale, yields fall, and the purification train has to be redesigned and revalidated. This is why peptide capacity cannot be conjured quickly: reactors can be installed, but the process knowledge of how to make a specific long peptide reliably and economically must be accumulated programme by programme.
That process knowledge is the real asset in this acquisition. Samsung Biologics has built its business as a contract manufacturer of biologic medicines, but biologics and peptides are different production worlds: one grows cells, the other builds chains of amino acids by chemistry. What PolyPeptide brings is precisely the expertise Samsung lacks in peptide synthesis, purification, and scale-up, which is why the premium attaches to a specialty CDMO rather than to generic manufacturing capacity.
PolyPeptide reports 37 Phase III projects, up from 30 before the reported increase. Seven additional late-stage programmes is a substantial expansion for a CDMO of this scale, and it carries a forward-looking implication: each Phase III programme that succeeds will eventually generate commercial manufacturing demand. The buyer is underwriting that future demand with the offer of CHF 44.31 per share.
The pipeline and the revenue base point in the same direction. With metabolic therapeutics contributing about 68% of revenue, the late-stage portfolio is likely concentrated in the same therapeutic area, although PolyPeptide has not named the specific programmes. The roughly 72% share of business attributed to large pharma companies, whatever its base, suggests that most of these Phase III projects are sponsored by customers with the capital and the regulatory capability to take a peptide drug through approval and launch.
The customer concentration cuts both ways. A CDMO whose customers are mostly large pharmaceutical companies benefits from long-term framework agreements and the reliability of well-funded sponsors. But the same concentration makes the business sensitive to the development decisions of a small number of companies, and it means PolyPeptide's capacity planning is largely driven by the pipelines of big pharma rather than by the broader biotech community. The disclosed figures do not reveal how much of the 72% rests with any single customer.
Geography completes the strategic picture. Samsung Biologics says the acquisition will broaden its service portfolio into peptides, including GLP-1, and expand its geographic reach in the US, Europe, and India. PolyPeptide described the transaction as intended to give it resources, investment capacity, and a strategic platform for its next phase of growth and innovation. Neither side has itemized the manufacturing sites or capacities that would transfer, leaving the operational detail of what Samsung is buying unresolved.
Peptides referenced: Glucagon, GLP-1.
Related reading: Peptide manufacturing capacity grows but pipeline diversity poses challenges, SG Bachem/Walporzheim U17 Squad Details for 2025-26 Season, Novadose and Pure Pharmaceuticals Lead Peptide Science Advances, Peptide and Oligonucleotide CDMO Market to Hit USD 11.42 Billion by 2035.